Strattera (Atomoxetine) Withdrawal: Does Stopping Cause Symptoms?

Yes, some people get symptoms when they stop Strattera (atomoxetine), even though the clinical trials say they should not. The drug clears fast, with a half-life of about 5 hours in most people, so anything you feel usually starts within 1 to 3 days and settles inside 2 to 4 weeks. Most of what gets called Strattera withdrawal is a mix of two things: real short-term noradrenergic rebound, and the return of ADHD symptoms that the drug had been covering. Telling those two apart is the whole game, because they need opposite responses.

Does Strattera actually cause withdrawal?

The official answer is no, and the patient-reported answer is sometimes. Both are defensible, and the gap between them is why so many people feel gaslit when they raise this with a prescriber.

Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor. It is not a stimulant and not a controlled substance, so it does not produce the crash-and-craving pattern people expect from Adderall or Vyvanse. The manufacturer studied abrupt discontinuation directly. In a prospective, placebo-controlled assessment published in the Journal of Clinical Psychopharmacology, Wernicke and colleagues found no discontinuation syndrome after atomoxetine was stopped abruptly in children and adults. The FDA prescribing information for Strattera reflects that finding and states the drug may be discontinued without being tapered.

That is the evidence base, and it is genuinely reassuring for most people. It is also narrow. Those trials ran weeks to months, in carefully screened participants, using symptom scales built to measure ADHD rather than withdrawal. Someone who has taken 80 mg for six years, alongside an antidepressant, is not represented in that data. Post-marketing reports and community accounts describe fatigue, low mood, irritability, headaches, nausea, sweating, and disrupted sleep in the first weeks off.

Bottom line: Strattera withdrawal is not a formal syndrome and most people stop without much trouble, but a minority get a real, short, self-limiting set of symptoms that the trials were not designed to catch.

Why does stopping Strattera make some people feel bad?

Because norepinephrine signaling adjusts to the drug, and it takes time to readjust when the drug leaves. Atomoxetine blocks the norepinephrine transporter, raising norepinephrine in the prefrontal cortex. Sustained blockade downregulates the system's own tone. Remove the blockade and, for a stretch, the system runs under-driven.

Norepinephrine drives alertness, blood pressure, gut motility, sweating, and sleep architecture, which is exactly why the reported symptoms cluster the way they do. Crushing fatigue, brain fog, standing dizziness, loose stools or nausea, and waking at 3am are noradrenergic signatures, not imagination.

Timing matters, and here Strattera is unusual. The FDA label reports a mean plasma half-life of about 5 hours in extensive metabolizers, but roughly 21 hours in the 7% of people who are CYP2D6 poor metabolizers. If you are a fast metabolizer, the drug is essentially gone in a day and any rebound hits hard and early. If you are a poor metabolizer, or you take a CYP2D6-inhibiting antidepressant like paroxetine or fluoxetine alongside it, the drug self-tapers over several days and the landing is softer.

There is a second mechanism worth naming. Atomoxetine has mild antidepressant activity for some people. Stopping it can drop mood in a way that has nothing to do with attention, and gets misread as "the depression coming back."

Bottom line: Short half-life plus adapted noradrenergic tone equals a fast, sharp, usually brief adjustment period.

What is the Strattera withdrawal timeline?

Symptoms typically begin within 1 to 3 days of the last dose, peak in the first week, and fade over 2 to 4 weeks. Here is what people most often describe, alongside how to read each phase.

| Time since last dose | Common experience | Most likely cause | ||---| | Day 1 to 3 | Fatigue, headache, nausea, dizziness on standing, irritability | Drug clearance and noradrenergic rebound | | Day 4 to 10 | Peak brain fog, low mood, disrupted sleep, tearfulness, appetite jumps | Rebound plus early ADHD symptom return | | Week 2 to 4 | Physical symptoms fade; focus problems remain and may feel worse than before | Mostly unmasked ADHD, not withdrawal | | Month 2 and beyond | Stable but untreated ADHD baseline; no new physical symptoms | Underlying condition, needs its own plan |

The single most useful diagnostic is the shape of the curve. True withdrawal symptoms improve week over week. Returning ADHD does not improve, because it is not a withdrawal process at all. It is your untreated baseline, and it feels worse than you remember because you now have a clear comparison.

Appetite is the clearest example. Atomoxetine suppresses appetite for many people. Appetite returning with a vengeance in week 1 is not a symptom of anything wrong. It is your body without the drug.

Bottom line: If it is still getting worse at week 4, it is almost certainly ADHD or a mood condition, not Strattera withdrawal, and the answer is a treatment plan rather than waiting it out.

Do you need to taper off Strattera, or can you just stop?

The label permits stopping abruptly, and for short-term or low-dose use that is usually fine. For long-term use at higher doses, tapering over several weeks is the safer default even though no guideline requires it.

The reasoning is straightforward. Tapering costs you almost nothing, and it converts an all-or-nothing experiment into something you can steer. If you step down and feel rough, you have information and a place to pause. If you stop cold and feel rough, you have no intermediate position to return to except restarting at full dose.

The principle that carries over from the wider deprescribing literature is proportional reduction. Horowitz and Taylor's 2019 paper in The Lancet Psychiatry showed that transporter occupancy follows a hyperbolic curve, so equal milligram cuts produce progressively larger biological effects as the dose gets lower. Hyperbolic tapering is the practice of reducing by a percentage of your current dose rather than a fixed number of milligrams, so each step feels roughly the same. The same receptor-occupancy math applies to the norepinephrine transporter that atomoxetine binds. The final steps down are the big ones, not the first.

The Maudsley Deprescribing Guidelines apply this framework across psychotropics and are the reference to hand a prescriber who has never tapered anything more gradually than halving a dose.

Practical constraint: Strattera capsules must not be opened. The FDA label warns the contents are an ocular irritant, so bead counting and capsule splitting are off the table. That leaves stepping between manufactured strengths of 10, 18, 25, 40, 60, 80, and 100 mg, or asking about a compounded oral suspension, which lets a compounding pharmacy make smaller reductions than the capsules allow. Alternate-day dosing is a poor substitute given the short half-life in most people, since it creates a sawtooth of on and off days rather than a gradual decline.

Bottom line: You can stop abruptly, but stepping down through available strengths, or a compounded liquid for the last stretch, gives you control you cannot get any other way.

How do you tell Strattera withdrawal from returning ADHD?

Look at the symptom type first, then the direction of travel. Withdrawal produces symptoms you did not have before starting the drug. Returning ADHD reproduces symptoms you had for years.

Dizziness, nausea, sweating, headaches, and flu-like malaise are not ADHD symptoms. They did not exist at your baseline, they appeared within days of the last dose, and they resolve. Those are withdrawal. Losing your keys, opening 14 tabs, missing deadlines, and interrupting people are your baseline. They are not withdrawal, and no amount of waiting will fix them.

Mood sits in between and needs care. Low mood in week 1 that lifts by week 3 is rebound. Low mood that deepens through week 4, especially with hopelessness or self-harm thoughts, needs prompt clinical attention. Strattera carries a boxed warning for suicidal ideation in children and adolescents, and while that warning is about starting the drug, the transition period off it deserves the same vigilance.

The NICE guideline on ADHD diagnosis and management (NG87) recommends structured review of whether medication is still needed, including planned trial periods off treatment, which is exactly the framework that turns "I quit and I feel awful" into a measurable experiment.

Write things down while you do it. Tracking a small set of ratings daily beats trying to remember week 2 from week 5, and it is the difference between a real answer and a guess. Our symptom journal exists for this, and the tapering plan worksheet helps you decide your steps before you are in the middle of them.

Bottom line: New physical symptoms that fade are withdrawal; old cognitive symptoms that persist are ADHD, and only one of them gets better by waiting.

Who is most likely to have a rough time coming off atomoxetine?

Duration and dose predict most of it. People who have taken atomoxetine for years at 60 mg or above report more trouble than people who took 25 mg for four months.

Metabolism is the second factor. CYP2D6 poor metabolizers carry higher plasma concentrations at any given dose, so there is further to fall, though their slower clearance partly cushions the descent. Anyone taking a strong CYP2D6 inhibitor is functionally in the same category. Stopping both drugs close together compounds the problem, which is a good reason to change one thing at a time.

Co-occurring anxiety or depression is the third. Atomoxetine's noradrenergic effect can be doing quiet work on anxiety or mood that nobody attributed to it, and removing it exposes that. This is where people conclude their mental health is collapsing when what happened is that a partially effective treatment stopped.

Life context matters more than clinicians usually credit. Coming off during exam season, a job change, or a newborn's first months guarantees you will not be able to separate drug effects from circumstance. Pick a boring stretch of calendar.

Community accounts collected by Mad in America and the tapering forums at Surviving Antidepressants describe this pattern across noradrenergic and serotonergic drugs alike: the people with the hardest time are almost always those on the longest exposures who reduced fastest.

Bottom line: Long exposure, higher dose, slow metabolism, and an unstable month are the four risk multipliers, and three of them are things you can plan around.

What actually helps during the transition?

Sleep, protein, and salt handle most of the physical symptoms, and structure handles the cognitive ones. This is unglamorous and it works.

Dizziness on standing is common because norepinephrine supports blood pressure. Adequate fluids and not skipping salt help; standing up slowly helps more than it sounds like it should. Nausea usually responds to eating smaller amounts more often rather than to anything pharmaceutical.

Fatigue in weeks 1 and 2 is real and it is temporary. Fighting it with caffeine escalation tends to wreck sleep, which makes week 3 worse. Protecting a consistent sleep window is the single highest-yield thing you can do, because sleep loss mimics almost every withdrawal symptom on the list.

For the ADHD symptoms that surface as the drug leaves, external structure substitutes for the internal kind. Written lists, timers, single-tasking, and calendar blocking are not a cure and they are not a lesser option. They are what the evidence supports for non-medication management, and they work better when set up in advance rather than improvised at week 2.

If you want clinical backup for this, a prescriber who understands deprescribing rather than only prescribing makes a large difference. Our directory of deprescribing-informed clinicians is one place to start, and deprescribing.org publishes the general framework such clinicians work from.

Bottom line: Sleep protection, hydration and salt, smaller frequent meals, and pre-built external structure cover the great majority of what the first month throws at you.

Frequently asked questions

How long does Strattera withdrawal last?

Physical symptoms usually start within 1 to 3 days and resolve within 2 to 4 weeks. Anything that is still worsening at week 4 is more likely untreated ADHD or a mood condition than atomoxetine withdrawal, and should be assessed rather than waited out.

Can I stop Strattera cold turkey?

The FDA label says atomoxetine may be discontinued without tapering, and short-term or low-dose users often do this without issue. After long-term use at 60 mg or more, stepping down over several weeks is the more controllable option, because it gives you somewhere to pause if symptoms appear.

Is atomoxetine addictive?

No. Atomoxetine is not a controlled substance and does not produce craving, euphoria, or dose escalation. Physical adjustment after stopping is not the same thing as addiction, and it does not mean you were dependent in the way people mean when they use that word.

Why do I feel worse off Strattera than I did before I started it?

Usually contrast rather than damage. You now know what treated attention felt like, so untreated attention registers as a loss instead of a baseline. Short-term noradrenergic rebound layers on top of that for the first week or two and exaggerates the effect.

Can I open Strattera capsules to make smaller doses?

No. The FDA label warns that capsule contents are an ocular irritant, so opening them is unsafe. To go below the smallest capsule, ask your prescriber about a compounded oral suspension, which allows finer reductions than the manufactured strengths permit.

Where to go from here

Most people come off atomoxetine without much drama, and the ones who struggle are usually reacting to a fast stop after long exposure. Plan the steps, pick a stable month, track what happens, and treat the ADHD that shows up underneath as its own question rather than as a failed taper. The Strattera drug profile has dosing and interaction details, and Wellbutrin is worth reading if you are taking both, since the two overlap on noradrenergic effects.

If you want to compare notes with people going through it now, the forums are free and moderated. Bring your tracking data. It makes the conversation far more useful than "I feel bad."

This article is for information only and is not medical advice. Do not start, change, or stop any prescription medication without talking to a qualified prescriber who knows your history.